Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what progress he has made on opening the Scarborough Community Diagnostic Centre.

Answered by Karin Smyth - Minister of State (Department of Health and Social Care)

The Scarborough Gateway Community Diagnostic Centre (CDC) has been delivering diagnostic activity since October 2023 from a temporary location at Bridlington Hospital. To date, the CDC has delivered 57,962 diagnostic tests, including magnetic resonance imaging, computed tomography, phlebotomy, and echocardiography.

The permanent site at Great Hill, Scarborough, is scheduled to begin delivering activity in February 2026. The CDC is expected to become fully operational in March 2026 and in April 2026 it will offer at least one service with 12 hours a day, seven days a week extended hours.

This supports the Government’s commitment in the Elective Reform Plan to open CDCs 12 hours per day, seven days a week so that patients can access vital diagnostic tests around their busy working lives. 103 CDCs are now open across these extended hours, an increase of 40 since July 2024.

The Elective Reform Plan commits to transform and expand diagnostic services and speed up waiting times for tests, a crucial part of reducing overall waiting times and returning to the referral to treatment 18-week standard.

Question to the Department for Science, Innovation & Technology:

To ask the Secretary of State for Science, Innovation and Technology, what plans her Department has to support the use of combinatorial genomic analysis techniques, such as those used by Precision Life to identify novel ME genetic associations, within government-funded research programmes.

Answered by Kanishka Narayan - Parliamentary Under Secretary of State (Department for Science, Innovation and Technology)

The Medical Research Council (MRC), which is part of UK Research and Innovation (UKRI), funds a broad portfolio of health research, including researcher led proposals using combinatorial genomic analysis. MRC has prioritised research into Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) for many years, investing over £4.65 million since 2020, and continues to welcome high quality applications in this area.

UKRI supports collaboration between Government funded bodies and private sector researchers across its councils and Innovate UK. This includes funding the LOCOME study led by Precision Life, through Innovate UK’s Advancing Precision Medicine programme, which supports the development of digital and data tools to improve diagnosis and treatment. MRC also enables academic-industry partnerships through its Industry Collaboration Framework.

UKRI does not typically maintain disease‑specific research strategies, instead providing open funding routes for the most impactful research across disciplines. Targeted work can be supported where needed. For example, in 2020, the National Institute for Health and Care Research (NIHCR), the Scottish Government and MRC funded the James Lind Alliance Priority Setting Partnership to identify ME/CFS research priorities.

Question to the Department for Science, Innovation & Technology:

To ask the Secretary of State for Science, Innovation and Technology, what plans her Department has to develop a long-term research strategy into under-researched health conditions that reflects the scale of emerging genetic evidence identified by private-sector research organisations, including Precision Life’s LOCOME study.

Answered by Kanishka Narayan - Parliamentary Under Secretary of State (Department for Science, Innovation and Technology)

The Medical Research Council (MRC), which is part of UK Research and Innovation (UKRI), funds a broad portfolio of health research, including researcher led proposals using combinatorial genomic analysis. MRC has prioritised research into Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) for many years, investing over £4.65 million since 2020, and continues to welcome high quality applications in this area.

UKRI supports collaboration between Government funded bodies and private sector researchers across its councils and Innovate UK. This includes funding the LOCOME study led by Precision Life, through Innovate UK’s Advancing Precision Medicine programme, which supports the development of digital and data tools to improve diagnosis and treatment. MRC also enables academic-industry partnerships through its Industry Collaboration Framework.

UKRI does not typically maintain disease‑specific research strategies, instead providing open funding routes for the most impactful research across disciplines. Targeted work can be supported where needed. For example, in 2020, the National Institute for Health and Care Research (NIHCR), the Scottish Government and MRC funded the James Lind Alliance Priority Setting Partnership to identify ME/CFS research priorities.

Question to the Department for Science, Innovation & Technology:

To ask the Secretary of State for Science, Innovation and Technology, what mechanisms are in place to support collaboration between Government-funded bodies and private-sector researchers following the identification of multiple biological pathways implicated in ME by the LOCOME study.

Answered by Kanishka Narayan - Parliamentary Under Secretary of State (Department for Science, Innovation and Technology)

The Medical Research Council (MRC), which is part of UK Research and Innovation (UKRI), funds a broad portfolio of health research, including researcher led proposals using combinatorial genomic analysis. MRC has prioritised research into Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) for many years, investing over £4.65 million since 2020, and continues to welcome high quality applications in this area.

UKRI supports collaboration between Government funded bodies and private sector researchers across its councils and Innovate UK. This includes funding the LOCOME study led by Precision Life, through Innovate UK’s Advancing Precision Medicine programme, which supports the development of digital and data tools to improve diagnosis and treatment. MRC also enables academic-industry partnerships through its Industry Collaboration Framework.

UKRI does not typically maintain disease‑specific research strategies, instead providing open funding routes for the most impactful research across disciplines. Targeted work can be supported where needed. For example, in 2020, the National Institute for Health and Care Research (NIHCR), the Scottish Government and MRC funded the James Lind Alliance Priority Setting Partnership to identify ME/CFS research priorities.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, whether his Department will be assessing the impact of new developments in Myalgic Encephalomyelitis and Long Covid research, such as the findings of the LOCOME project, on health policy towards those living with long term health conditions.

Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)

On 6 November, the National Institute for Health and Care Research (NIHR) and the Medical Research Council (MRC) jointly hosted a showcase event for post-acute infection conditions research, which included a review of the DecodeME research project and the PrecisionLife study on myalgic encephalomyelitis (ME) and long COVID research. PrecisionLife is leading on the LOCOME, or LOng COvid and Myalgic Encephalomyelitis Diagnostics Stratification, project. The showcase event was attended by speakers from a range of disciplines, including researchers, people with lived experience, ME charities, NIHR and MRC representatives, as well as Government officials.

The Department is always very keen to reflect newly emerging research findings in its policy-making.

Found: the meeting Members present: Bob Blackman (Chair); Jonathan Davies; Mr Lee Dillon; Mary Glindon; Alison Hume

Found: Conservative; Bognor Regis and Littlehampton) Chris Hinchliff (Labour; North East Hertfordshire) Alison Hume